Previous close | 0.2600 |
Open | 0.4900 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 60.00 |
Expiry date | 2024-06-21 |
Day's range | 0.4700 - 0.4900 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
REDWOOD CITY, Calif. & SANTA MONICA, Calif., May 09, 2024--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder.
Unraveling the Financial Dynamics and Strategic Directions of Gilead Sciences Inc (GILD)